Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07766434

A Prospective Multicenter Real-World Registry of Quantitative Flow Ratio-Guided Coronary REvascularization and QuAlity evaLuation

This prospective, multicenter observational registry aims to establish a QFR-based quality control standard system for coronary revascularization in patients with coronary artery disease. The study will enroll over 10,000 patients with visually estimated at least one main branch coronary stenosis ≥50% from more than 50 centers across China (covering provincial, municipal, and county-level hospitals). Coronary angiographic images and intracoronary imaging (if available) will be collected and retrospectively analyzed by an independent core laboratory. The primary endpoint is QFR acquisition accessibility, defined as the mean of QFR usage proportion across centers.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

National Clinical Research Center of Cardiovascular Diseases, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, 100037, China

Location contact

Fuwai hospital

CONTACT

[email protected]

010-88322674

About this study

This is a prospective, multicenter, observational registry study conducted at more than 50 centers across China. Patients with coronary angiography showing visually estimated at least one main branch stenosis ≥50% who undergo PCI or receive conservative treatment for acute coronary syndrome (including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction >4 weeks after onset) or chronic coronary syndrome (including stable angina and asymptomatic myocardial ischemia) will be consecutively enrolled. Coronary angiographic images will be submitted to an independent core laboratory for retrospective QFR analysis. The study will establish a QFR-based quality control standard system for coronary revascularization.

Prespecified subgroup analyses will be performed to assess the concordance rates, overtreatment, and undertreatment rates between clinical decisions and offline core laboratory QFR, and to explore heterogeneity across hospital levels, clinical presentations, disease complexity, target vessel, operator annual PCI volume, QFR image analyzability, and lesion morphology. Other prespecified subgroups will be analyzed for the primary and secondary endpoints, including age, sex, diabetes, smoking status, acute coronary syndrome, body mass index, left ventricular ejection fraction, lesion location, length and reference vessel diameter, stenosis severity, multivessel disease, calcified lesion, bifurcation, tandem and bending/tortuous lesion, QFR gray zone (0.75-0.85), QFR based functional and residual functional SYNTAX score, residual QFR, center experience for invasive physiology, and learning experience with QFR.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Coronary angiography showing visually estimated at least one main branch coronary stenosis ≥50% in patients with acute coronary syndrome (including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction >4 weeks after onset) or chronic coronary syndrome (including stable angina and asymptomatic myocardial ischemia) who undergo PCI or receive conservative treatment
  • Ability to understand the study design and provide written informed consent

Exclusion criteria

  • ST-segment elevation myocardial infarction within 4 weeks of onset
  • History of coronary artery bypass grafting (CABG) or planned CABG within 6 months
  • Inability to undergo coronary angiography
  • Non-cardiac cause with expected survival <1 year
  • Other conditions that may interfere with follow-up (e.g., dementia, substance abuse including drug addiction and other drug dependencies)
  • Refusal to participate in the study

Treatment and study plan

Primary outcomes

  1. QFR Adoption Rate

    Time frame: At enrollment (baseline)

    Defined as the mean across participating centers of the proportion of patients undergoing QFR assessment among eligible patients at each center.

Secondary outcomes

  1. MACE

    Time frame: 6 month, 1 year, 3 years, and 5 years

    A composite of all-cause mortality, any myocardial infarction and any ischemia-driven revascularization

  2. Death

    Time frame: 6 months, 1 year, 3 years, and 5 years

    Cardiovascular, non-cardiovascular and undetermined death

  3. MI

    Time frame: 6 months, 1 year, 3 years, and 5 years

    Target vessel related and non-target vessel related MI

  4. Target vessel revascularization (TVR)

    Time frame: 6 months, 1 year, 3 years, and 5 years

    The ischemia driven and non-ischemia driven TVR

  5. Any coronary artery revascularization

    Time frame: 6 months, 1 year, 3 years, and 5 years

    The ischemia driven and non-ischemia driven Revascularization

  6. Definite or probable stent thrombosis

    Time frame: 6 months, 1 year, 3 years, and 5 years

    Definite and probable stent thrombosis during acute, sub-acute, late, and very late phase according to the Academic Research Consortium (ARC)-2

Study contacts

Contact information is provided by the study sponsor or research team.

Jie Qian, PhD

CONTACT

[email protected]

010-88396089

Sponsors and collaborators

Lead sponsor

China National Center for Cardiovascular Diseases

Other Gov

Collaborators

  • First Affiliated Hospital Xi'an Jiaotong University
  • Fuwai Huazhong Cardiovascular Hospital
  • Fuwai Yunnan Cardiovascular Hospital
  • Guangdong Provincial People's Hospital
  • Second Hospital of Jilin University
  • Sir Run Run Shaw Hospital

Registry information

Acronym: QFR-REAL

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Aug 14, 2026
Registry last updated
Aug 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.